MAPT and Alzheimer disease: Struyfs et al. (2015) analyzed the Aβ1-42, T-tau, and P-tau levels in patients with MCI and AD, but did not compare them with DKI parameters. In other diseases, Lo et al. (2022) studied the correlation of blood tau and Aβ1-42 with DKI parameters in patients with fibromyalgia, but up to date, no one has compared AD pathological biomarkers with DKI. Our study was originally conceived to include in vitro pathological studies of AD, but few patients and their families accepted it because of its high cost and invasiveness.